If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Verzenio ® (abemaciclib) tablets
50mg, 100mg, 150mg, 200mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Verzenio® (abemaciclib): FDA Approval and Indication
Abemaciclib has been approved for treatment of HR+/HER2− advanced or metastatic breast cancer in combination with an NSAI, fulvestrant, or as monotherapy.
On September 28, 2017, the FDA approved VERZENIO® (abemaciclib) for use
in combination with fulvestrant for the treatment of women with HR+, HER2- advanced or MBC with disease progression following ET, and
as monotherapy for the treatment of adult patients with HR+, HER2- advanced or MBC with disease progression following ET and prior chemotherapy in the metastatic setting.1
On February 26, 2018, the FDA approved abemaciclib for use
in combination with an AI as initial endocrine-based therapy for the treatment of postmenopausal women with HR+, HER2- advanced or MBC.1
Enclosed Prescribing Information
VERZENIO® (abemaciclib) tablets, for oral use, Lilly
VERZENIO® (abemaciclib) patient information, Lilly
1. Verzenio [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
AI = aromatase inhibitor
ET = endocrine therapy
FDA = Food and Drug Administration
HER2- = human epidermal growth factor receptor 2-negative
HR+ = hormone receptor-positive
MBC = metastatic breast cancer
NSAI = nonsteroidal aromatase inhibitor
Date of Last Review: January 02, 2019
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 8am - 7pm ET
